AltaThera Pharmaceuticals

AltaThera Pharmaceuticals is a private, precision medicine company dedicated to solving serious and costly problems in cardiovascular care through innovative science. Its core strategy utilizes model-informed drug development (MIDD) to identify new uses and optimal dosing for existing drugs, starting with its commercialized product, Sotalol IV, for atrial fibrillation. The company's mission centers on improving efficiency, effectiveness, and patient outcomes by converting inpatient procedures to outpatient, thereby reducing healthcare costs. With a team based across the country and a culture built on humility, adaptability, and intellectual curiosity, AltaThera is positioned to expand its pipeline beyond its initial cardiovascular focus.

A Model-Informed Drug Development (MIDD) platform that uses human clinical data to create exposure-based, biological, and statistical models for identifying new uses and optimal dosing regimens for existing drugs.

Total raised: $35M

AltaThera's Sotalol IV primarily competes with the standard multi-day inpatient oral sotalol loading protocol. Its main differentiation is reducing hospital length of stay. As a MIDD company, it competes with other modeling-focused firms but integrates the platform directly into its own product development, creating a unique end-to-end capability.